Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akoya Biosciences Inc (NQ: AKYA )

2.880 -0.060 (-2.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 240,153
Open 2.940
Bid (Size) 2.560 (5)
Ask (Size) 2.960 (75)
Prev. Close 2.940
Today's Range 2.850 - 2.960
52wk Range 1.880 - 6.310
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A Closer Look at 4 Analyst Recommendations For Akoya Biosciences
Via Benzinga
AKYA Stock Earnings: Akoya Biosciences Meets EPS, Misses Revenue for Q2 2024
AKYA stock results show that Akoya Biosciences met analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-39.75%
-39.75%
1 Month
+17.55%
+17.55%
3 Month
+34.58%
+34.58%
6 Month
-42.74%
-42.74%
1 Year
-32.08%
-32.08%

More News

Read More
Akoya Biosciences Reports Second Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
Analyst Scoreboard: 4 Ratings For Akoya Biosciences
Via Benzinga
Recap: Akoya Biosciences Q4 Earnings
Via Benzinga
Earnings Outlook For Akoya Biosciences
Via Benzinga
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Alcon Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
AKYA Stock Earnings: Akoya Biosciences Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Akoya Biosciences Reports First Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
From Akoya Biosciences, Inc.
Via GlobeNewswire
AKYA Stock Earnings: Akoya Biosciences Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
From Akoya Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For March 4, 2024
Via Benzinga
Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
From Akoya Biosciences, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.